颈静脉和后腔静脉导管安置方法

在动物体内不同部位安置颈静脉导管是进行生殖内分泌研究的重要基本方法之。本文介绍了奶山羊颈静和后腔静脉导管的安置和使用方法。导管为长约１米、内径１、５ｍｍ、外径２．２ｍｍ的硅胶管。导管插入血管的深度约为８－１０ｃｍ，另一端在皮下潜行约２０－２５ｃｍ后穿出体外，并安装带盖针头。每次采样后在导管内注满稀释为４０单／ｍｌ的肝素以防止血液凝结在导管内，防止经导管注入气泡或引起感染，一般可维持两以上连续采样。     

大鼠肝移植肝上下腔静脉不同缝合方式及手术体会

目的:探讨肝上下腔静脉不同缝合方式对大鼠原位肝移植的影响.方法:选取雄性SD大鼠60对,以SD大鼠为供体和受体,随机分成A、B两组,每组30对.两组均采用改良Kamada"二袖套法"进行大鼠原位肝移植,A组采用双定点连续缝合方式吻合肝上下腔静脉,B组采用单定点连续缝合方式吻合.比较两组肝上下腔静脉吻合时长、无肝期时长以...     

PC预处理异体生物材料的应用前景

同种异体血管移植前,必须经过物理或化学方法的预处理,以封闭氨基酸残基,降低抗原性。化学法有甲醛、酒精、柳硫汞、戊二醛(Gluteraldehyde,GA)等,其中又以GA最为常用。但是经GA交联的血管、瓣膜存在钙化变性、组织僵硬、耐久性差的缺点,因此需要寻找新的处理试剂。多聚环氧化合物(Polyepoxy compound,PC)处理的生物材     

磁性纳米生物材料在医学上的应用

磁性纳米生物材料因其独特的性能而具有广泛的应用价值,尤其在肿瘤治疗,细胞及生物分子的分离纯化,临床诊断和组织工程领域,给人类疾病的治疗带来了新的契机和希望。本文介绍和评估了国内外纳米磁粒在医学应用上的进展,并展望了其未来。     

天然降解性生物材料在整形外科中的应用

整形外科与生物医用材料有着密切的关系。互为依存且互促发展,本文将近年来新型的生物医用材料结合本研究所多年来的科研。重点阐述胶原蛋白,透明质酸及医用几丁糖的基本情况,并努力探索他们在整形外科中可能的应用。     

基因工程功能化丝蛋白生物材料及其在生物医学中的应用

丝蛋白生物材料具有优异的力学性能、良好的生物相容性及可降解性,在生物医学领域具有巨大的应用潜力。现有丝蛋白生物材料在结构和功能方面的相关知识,为设计合成新型丝蛋白生物材料提供了理论基础。此外,利用基因工程技术可将编码新肽或结构域的基因序列添加到编码丝蛋白的基因序列中,以获得具有新功能的丝蛋白生物材料,并更好地满足现代生物医学的需求。文中总结了基因工程功能化的丝蛋白生物材料在生物医学领域中的应用现状和发展前景。     

鳖源胶原蛋白提取纯化及在生物材料中的应用

近年来,胶原蛋白因其良好的生物学性能在生物材料应用中得到越来越多的关注,为了建立一种快速高效的鳖源胶原蛋白纯化方法和探究其在生物材料中的应用价值,首先用Van Gieson染色法和苦味酸-天狼星红染色法观察裙边胶原纤维组织结构,发现裙边胶原纤维含量非常高且类型主要是Ⅰ型。采用不同截留分子量的透析袋对裙边胶原蛋白粗提液进行直接透析纯化,发现截留分子量为100 k Da的透析袋在透析48 h后对裙边胶原蛋白的纯化效果最好,SDS-PAGE检验显示几乎没有杂带。对裙边胶原蛋白生物学性能包括吸水性、体外降解性进行考察,其吸水力和持水力分别高达12.06 g/g和98.21%,且在72 h后被完全降解;对裙边胶原蛋白海绵的溶血性、皮肤致敏性、肝部创伤止血性、促创伤皮肤愈合性进行了研究,并和交联胶原进行比较,发现裙边胶原蛋白和交联胶原均不会造成SD大鼠溶血和皮肤过敏,二者均具有良好的止血效果,且裙边胶原蛋白能显著缩短创伤皮肤愈合时间,具有良好的促创伤皮肤愈合性,而交联胶原效果欠佳。本研究表明裙边胶原蛋白表现出了优良的生物学性能,在生物材料领域具有很大应用价值。     

生物材料低温介电损耗机理的研究

研究了几种生物材料在低温冷冻过程中的介电损耗特性。通常,在室温和较低的频率下生物材料由于含有大量的水分而表现出很高的介电常数;而在低温冷冻过程中,生物材料的介电常数会由于水分变成冰晶产生一个由１０６数量级到１０２数量级的突变,同时介质损耗角正切ｔｇδ出现峰值,出现峰值的温度和材料的组成和含水量有关。介电常数和介质损耗角正切对温度的变化率可以反映出材料中冰晶的体积分数。因此,通过研究在低温下生物材料的介电极化和损耗现象,可以建立介电谱和相变或介电谱和细胞存活率之间的关系。     

中国生物材料专利保护及其现状分析

本文叙述了我国生物材料专利制度的变迁,耐我国生物材料的专利保护范围进行了论述,对生物材料的保藏问题进行了说明;对我国生物材料保护制度进了论述,并对我国生物材料领域的专利现状进行了分析,就如何加强我国生物材料的专利保护提出几点建议。     

Treatment of Pacemaker-Induced Superior Vena Cava Syndrome by Balloon Angioplasty and Stenting

Superior vena cava (SVC) syndrome is a rare but serious complication after pacemaker implantation. This report describes three cases of SVC syndrome treated with venoplasty and venous stenting, with an average follow-up of 30.7 (±3.1) months. These cases illustrate that the definitive diagnosis, and the extent and location of venous obstruction, can only be determined by venography.     

A Novel Method of Placing Right Ventricular Leads in Patients With Persistent Left Superior Vena Cava Using a Conventional J Stylet

Background

Locating pacemaker electrodes can become complicated by congenital abnormalities such as persistent left superior vena cava (LSVC).

Objective

To evaluate a technique for the implanting of ventricular electrode in patients with persistent LSVC.

Materials and Methods

The study was carried out from June 2001 to June 2010 involving all patients who were admitted to the Hospital Universitario Mayor, Instituto de Corazon de Bogota and Hospital Universitario Clinica San Rafael (Bogota-Colombia) for implanting pacemakers or cardiac defibrillators. LSVC was diagnosed by fluoroscopic observation (anterior-posterior view) of the course of the stylet. Four steps were followed: 1) Move the electrode with a straight stylet to the right atrium. 2) Change the straight stylet by a conventional J stylet and push the electrode to the lateral or anterolateral wall of the right atrium. 3) Remove the guide 3-5 cm and 4) Push the electrode which crosses the tricuspid valve into the right ventricle and finally deploy the active fixation mechanism.

Results

A total of 1198 patients were admitted for pacemaker or cardiac defibrillator implant during the 9-year study period, 1114 received a left subclavian venous approach. There were 573 males and 541 females. Persistent LSVC was found in five patients (0.45%) Fluoroscopy time for implanting the ventricular electrode ranged from 60 to 250 seconds, 40 to 92 minutes being taken to complete the whole procedure.

Conclusion

We present a simple and rapid technique for electrode placement in patients with LSVC using usual J guide and active fixation electrodes with high success.     

Successful Implantation of Transvenous Pacing System via Persistent Left Superior Vena Cava and Coronary Sinus in Small Children

Transvenous pacemaker implantation tends to be difficult in the setting of a persistent left superior vena cava (SVC) and an absent or inaccessible right SVC. We report two small children in whom transvenous pacing leads were successfully inserted via a persistent left SVC. This technique was safe in our cases; however, favorable long-term result has yet to be demonstrated.     

原发性肝癌合并下腔静脉癌栓的手术治疗

目的：探讨原发性肝癌合并下腔静脉癌栓的手术治疗方法。方法：采用肝切除加下腔静脉取栓治疗2例肝癌合并下腔静脉癌栓患者,取栓方法包括经荷栓肝静脉取栓（1例）和下腔静脉切开取栓（1例）,又分在全肝血流阻断下取栓和在萨氏钳局部血管阻断下取栓。结果：2例肝癌及下腔静脉癌栓均得到成功切除,术中无明显并发症发生;术后无死亡;随访中一例存活11月;另1例已生存8个月。结论：肝癌合并下腔静脉癌栓的手术治疗安全可行,其基本术式为肝切除加下腔静脉切开取栓。     

原发性肝癌合并下腔静脉癌栓的手术治疗

目的:探讨原发性肝癌合并下腔静脉癌栓的手术治疗方法.方法:采用肝切除加下腔静脉取栓治疗2例肝癌合并下腔静脉癌栓患者,取栓方法包括经荷栓肝静脉取栓(1例)和下腔静脉切开取栓(1例),又分在全肝血流阻断下取栓和在萨氏钳局部血管阻断下取栓.结果:2例肝癌及下腔静脉癌栓均得到成功切除,术中无明显并发症发生;术后无死亡;随访中一例存活11月;另1例已生存8个月.结论:肝癌合并下腔静脉癌栓的手术治疗安全可行,其基本术式为肝切除加下腔静脉切开取检.     

Radiofrequency Catheter Ablation Of Atrioventricular Nodal Reentry Tachycardia In A Patient With Inferior Vena Cava Anomaly

Curative radiofrequency catheter modification of the slow pathway is the recommended therapy for patients suffering from recurrent symptomatic atrioventricular nodal reentry tachycardia. This is usually performed via femoral vein and the inferior vena cava (IVC). Presence of venous occlusion or complex venous anomaly involving the IVC may preclude this approach. Here, we report a case with a complex venous anomaly involving the inferior vena cava, who underwent electrophysiological study and successful radiofrequency ablation by an alternative approach.     

Implantation of Inferior Vena Cava Interposition Graft in Mouse Model

Biodegradable scaffolds seeded with bone marrow mononuclear cells (BMCs) are often used for reconstructive surgery to treat congenital cardiac anomalies. The long-term clinical results showed excellent patency rates, however, with significant incidence of stenosis. To investigate the cellular and molecular mechanisms of vascular neotissue formation and prevent stenosis development in tissue engineered vascular grafts (TEVGs), we developed a mouse model of the graft with approximately 1 mm internal diameter. First, the TEVGs were assembled from biodegradable tubular scaffolds fabricated from a polyglycolic acid nonwoven felt mesh coated with ε-caprolactone and L-lactide copolymer. The scaffolds were then placed in a lyophilizer, vacuumed for 24 hr, and stored in a desiccator until cell seeding. Second, bone marrow was collected from donor mice and mononuclear cells were isolated by density gradient centrifugation. Third, approximately one million cells were seeded on a scaffold and incubated O/N. Finally, the seeded scaffolds were then implanted as infrarenal vena cava interposition grafts in C57BL/6 mice. The implanted grafts demonstrated excellent patency (>90%) without evidence of thromboembolic complications or aneurysmal formation. This murine model will aid us in understanding and quantifying the cellular and molecular mechanisms of neotissue formation in the TEVG.